welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
suspended

Microdystrophin Gene Transfer Study in Adolescents and Children With DMD

key information

study id #: NCT03368742

condition: Duchenne Muscular Dystrophy

status: suspended

purpose:

This is a randomized, controlled, open-label, single-ascending dose study to evaluate the safety, tolerability and efficacy of SGT-001 in adolescents and children with Duchenne muscular dystrophy (DMD). Eligible patients will be randomized to an active treatment group or an untreated control group. Patients in the active treatment group will receive a single intravenous (IV) infusion of SGT-001 and will be followed for approximately 2 years. Patients in the untreated control group who continue to meet treatment criteria will receive SGT-001 after 1 year on study.

intervention: SGT-001

mechanism of action: Gene therapy to introduce a version of dystrophin

results: https://clinicaltrials.gov/ct2/show/results/NCT03368742

last updated: December 05, 2019

rareRelated